Abstract: A capsule composition comprising: (a) a polyester shell having a thickness of no more than 20 microns, and (b) a solution containing a visual and/or olfactory indicator, wherein the solution is encapsulated by the polyester shell. Also described herein is a method for detecting alpha particle radiation, in which: (i) the capsule composition is placed in contact with an esterase in a location where the presence of alpha particle radiation is being determined; (ii) waiting a period of time for the esterase to degrade the polyester shells, wherein the period of time is insufficient for the esterase to cause leakage of the solution in the absence of alpha particle radiation but is sufficient for alpha particle radiation, if present, to cause leakage from the capsule composition; and (iii) observing whether leakage has occurred at the end of the period of time to determine whether alpha particle radiation is present.

Abstract: Provided herein are compositions and kits including trichloroacetic acid, and methods of using the same for debridement during endodontic treatment.

Abstract: Microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary shells of shell material around the loading substance and cooling the aqueous mixture until the primary shells agglomerate and an outer shell of shell material forms around the agglomeration. Such microcapsules are useful for storing a substance and for delivering the substance to a desired environment.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: The present Invention deals with an alternative Interfacial polymerization process of microencapsulation, microcapsule's produced thereof, microencapsulated agrochemicals, pharmaceuticals, catalysts and phase transfer materials, and formulations thereof, by means of microcapsules and starting materials with the participation of acetylene carbamide derivatives in the final structure of the microcapsules' wall.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions.

Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: The present invention relates to a preparation method for a biodegradable polymer microparticle and a microparticle prepared by the method. More particularly, the present invention relates to a method for preparing a polymer microparticle, wherein the method includes the steps of: dissolving a biodegradable polyester-based polymer in DMSO (Dimethyl Sulfoxide); spraying the solution in a low temperature hydrocarbon solution to provide a frozen DMSO microparticle; adding the microparticle in a low temperature salt aqueous solution to dissolve DMSO; and removing salt. The present invention provides a method for preparing a novel polymer microsphere which can be injected through a syringe due to excellent physical properties (such as biocompatibility, biodegradability, porosity, mechanical strength) and the microcarrier's size-adjustability, and can be easily mass-produced.

Abstract: The present invention deals with an alternative interfacial polymerization process of microencapsulation, microcapsule's produced thereof, microencapsulated agrochemicals, pharmaceuticals, catalysts and phase transfer materials, and formulations thereof, by means of microcapsules and starting materials with much lower toxicological profile than customary microencapsulation materials, and with the participation of acetylene carbamide derivatives in the final structure of the microcapsules' wall.

Abstract: The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system comprises of microcapsules (200 to 600 ?m) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5.

Abstract: A process for producing a lactic acid polymer of 15,000 to 50,000 in weight-average molecular weight, the content of polymeric materials having not more than about 5,000 in weight-average molecular weight therein being not more than about 5% by weight, characterized by hydrolyzing a high molecular weight lactic acid polymer, placing the resultant solution comprising the hydrolyzed product under a condition capable of precipitating the objective lactic acid polymer, separating the precipitated lactic acid polymer and collecting them. The lactic acid polymer is useful as a matrix for sustained-release preparations. The sustained-release microcapsule preparation encapsulating a physiologically active substance can fully prevent the initial excessive release of the physiologically active substance from the microcapsules and keep a stable release rate over a long period of time.

Abstract: Described herein are microcapsules and emulsions prepared from low Bloom gelatin and methods of making and using thereof.

Abstract: A multi-layered microcapsule has an inner extracellular matrix and an outer shell. The inner extracellular matrix includes a first inner layer of biopolymer and a second intermediate layer of polymer that provides partial immune-protection and holds the first layer in place. The outer shell can form an exoskeleton to provide mechanical stability. Each of the individual layers can be varied to optimize mechanical stability, cell function, and immuno-protection.

Abstract: A method for controlling protozoa trophozites and cysts wherein biocides or control agents are encapsulated within microcapsules or manufactured into the core of liposomes, thereafter the biocide containing microcapsules or liposomes are then introduced into an aqueous system.

Abstract: The invention relates to novel microcapsule formulations of (A) a particulate disperse phase of microcapsules comprising (1) a polyurea and/or polyurethane coating with average layer thicknesses of between 5 and 20 nm, and (2) a capsule filling comprising at least one penetrant and, optionally, additives, and (B) a suspension comprising (1) at least one solid agrochemical active compound, (2) additives, (3) water, and (4) optionally, one or more agrochemical active compounds that are liquid at room temperature. The invention further relates to a process for the preparation of these microcapsule formulations and to their use for applying agrochemical active compounds.

Abstract: Microcapsules comprising an agglomeration of primary microcapsules, each individual primary microcapsule having a primary shell and the agglomeration being encapsulated by an outer shell, may be prepared by providing an aqueous mixture of a loading substance and a shell material, adjusting pH, temperature, concentration and/or mixing speed to form primary shells of shell material around the loading substance and cooling the aqueous mixture until the primary shells agglomerate and an outer shell of shell material forms around the agglomeration. Such microcapsules are useful for storing a substance and for delivering the substance to a desired environment.

Abstract: An aqueous microcapsule suspension liquid exhibiting an excellent (long-term) storage stability and allowing easy re-dispersion and dilution with water even after such a storage, is produced by adding a microorganism-fermented polysaccharide of succinoglycan type as a thickening agent into a microcapsule slurry, or by adding such a microorganism-fermented polysaccharide as a thickening agent to a microcapsule slurry after uniform dilution with water.

Abstract: This invention relates to a method for immobilizing cells under laminar flow conditions in a matrix formed by biocompatible charged polymers, to a flow device for the use with the method of the present invention, and to uses of the polymer matrices containing the cells immobilized using the method of the present invention.

Abstract: A method of forming microspheres of a bioactive material, such as a protein polymer or drug by nebulizing a solubilized form of a material to be encapsulated and an encapsulating material, such as albumin, in a stirred chilled solvent system comprising a vegetable oil, mineral oil and/or a lower alcohol such that the formed microspheres demonstrate intracellular bioactivity when taken up by macrophages.

Abstract: A safe delivery system of agriculturally active material is formed using an encapsulation process. A microencapsulated suspension of agriculturally active material includes an encapsulating agent formed from a graft copolymer of starch and at least one vinyl monomer.

Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.

Abstract: Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.

Abstract: The invention provides methods for treating post-surgical articular or incisional pain and/or discomfort in a patient. The invention further provides improved surgical methods and controlled release formulations for treating an articular injury of a joint in a patient, in which a collagen formulation is used in conjunction with a surgical procedure to treat the articular injury or the side effects of the surgical procedure. Collagen formulations of the invention and their use, in addition to the surgical procedure, may provide at least one or more of the following benefits: reduced patient pain, shortened recovery time and/or improved joint condition (including treatment of the underlying articular injury). Moreover, the methods and compositions of the invention can be used in conjunction with essentially any surgical procedure used to treat an articular injury.

Abstract: A process for making hydrophobicized powders of micro- and/or nanocapsules involving the steps of: (a) providing an aqueous polymer solution containing at least one active ingredient and at least one hydrophilic polymer; (b) providing an oil component heated to a temperature above a gel point of the aqueous polymer solution; (c) dispersing (a) in (b) in the presence of a water-in-oil emulsifier to form a dispersion; (d) cooling the dispersion to a temperature below the gel point of the aqueous polymer solution to form micro- and/or nanocapsules containing the active ingredient encapsulated therein; (e) harvesting the micro- and/or nanocapsules from the dispersion; and (f) contacting the micro- and/or nanocapsules with an oil-absorbing auxiliary ingredient.

Abstract: The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.

Abstract: A method of producing a controlled release form of an agricultural active material includes the provision of an organic liquid composition in which the active is present, but where the liquid composition is free from aromatic solvents and is maintained below the normal melting point of the active. The liquid composition is formed into small droplets and the droplets are enclosed by a non-water soluble shell to provide microcapsules, the shell of which is designed to release the agricultural active at a pre-selected controlled rate when the microcapsule is exposed to natural environmental conditions. Controlled release forms of agricultural actives are also provided.

Abstract: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.

Abstract: A multi-layered microcapsule has an inner extracellular matrix and an outer shell. The inner extracellular matrix includes a first inner layer of biopolymer and a second intermediate layer of polymer that provides partial immune-protection and holds the first layer in place. The outer shell can form an exoskeleton to provide mechanical stability. Each of the individual layers can be varied to optimize mechanical stability, cell function, and immuno-protection.

Abstract: A non-disruptive three-dimensional culture system allows cell growth and proliferation in three dimensions, permitting cell splitting without subjecting cells to disruptive conditions that affect cell structure and functions. An extracellular matrix provides a good environment for culturing or co-culturing anchorage-dependent cells. The cells cultured this manner can be readily used in such applications as cell transplantation, tissue engineering seeding of cells on scaffolds, and other applications that require immediate availability of functioning cells.

Abstract: A controlled-release additive composition for use in aqueous systems. The composition comprises a core containing at least one additive component and a polymeric coating encapsulating said core. The controlled released cooling additive composition slowly releases the additive components to aqueous system, thereby delivering an effective concentration level of additive components over an extended period.

Abstract: This invention relates to the production and use of encapsulated and/or concentrically-constructed fertilizer or bioremediation granules such as, for example, granules of 0.5 mm to 10 mm in diameter constructed so that there are at least two components to the granule including a core with a surrounding capsule or a core with one or more concentric layers that are distinguishable from the core with respect to nutrient content, density, hardness, solubility, composition, microbial content and permeability, as in permeability to odors or the permeability of nutrients that might volatize to the atmosphere or leach into the soil. The basic idea was to create a method for manufacturing and using fertilizer granules, which incorporate multiple concentric layers or a core plus an encapsulating outer layer.

Abstract: This invention relates to a composition for use in treating benign prostatic hyperplasia including a saw palmetto extract provided in an oral controlled release formulation which allows release of active ingredients in the intestinal tract and which allows the maintenance of therapeutic levels of active agents in the bloodstream for prolonged periods of time. This invention also relates to a composition for improving the efficacy of a saw palmetto extract, a method of treating benign prostatic hypertrophy, and a method of improving the efficacy of a saw palmetto extract treatment.

Abstract: The invention relates to microcapsule suspensions containing (A) a particulate disperse phase of microcapsules comprising: (1) sleeves that are reaction products of mixtures of toluylene diisocyanate and 4,4′-methylenebis-(cyclohexyl isocyanate) with at least one diamine and/or polyamine, and (2) a capsule filling comprising: (i) at least one solid insecticidally and/or herbicidally active compound, (ii) at least one liquid aliphatic hydrocarbon having a boiling point above 160° C., (iii) at least one oil-soluble polymeric dispersing agent, and (iv) optional agrochemically active compounds that are liquid at room temperature, and (B) a liquid aqueous phase comprising water, optional additives, and optional agrochemically active compounds in non-encapsulated form that are solid at room temperature.

Abstract: Disclosed is a sustained-release preparation comprising 1) a polymer of lactic acid having a weight-average molecular weight of about 25,000 to about 60,000 and 2) a physiologically active substance, and which releases the physiologically active substance over a period of at least about 5 months; the sustained-release preparation shows an almost continuous zero order release of the physiologically active substance over a period of as long as about 5 months.

Abstract: The invention relates to the use of one or more noble metals selected from silver, gold, platinum, and palladium but most preferably silver, in a nanocrystalline form, for the treatment of a hyperproliferative skin disorder or disease such as psoriasis. Among the noble metals, silver is preferred for such treatment. The nanocrystalline noble metal of choice may be used in the form of a nanocrystalline coating of one or more noble metals, a nanocrystalline powder of one or more noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more noble metals.

Abstract: The present invention includes a cosmetic formulation. The cosmetic formulation comprises a plurality of spheres having a first desiccated volume and having a second hydrated volume. The hydrated volume is greater than the desiccated volume.

Abstract: Compositions for sustained delivery of a biomolecule including an anionic polymer and a cationic polymer which ironically interact with each other and, optionally, with the biomolecule. Methods for making the compositions, including the step of combining the negatively charged polymer with the positively charged polymer to form an ionic complex are also provided. The biomolecule may be complexed with one of the polymers before it is complexed with the oppositely charged polymer. The complex is exposed to conditions that cause the formation of precipitated microcarriers, such as a change in pH or the addition of a complexing molecule. The compositions are preferably formulated into microcarriers.

Abstract: Methods for treating a movement disorder by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.

Abstract: The present invention provides a composition alleviated in a bitter taste or the like of a medicament. The present invention relates to a composition comprising a basic medicament having an unpleasant taste and polyvinylpyrrolidone and/or copolyvidone; or a method for alleviating an unpleasant taste of a basic medicament having the unpleasant taste by adding polyvinylpyrrolidone and/or copolyvidone. The present invention further provides a composition comprising (1) a basic medicament, (2) polyvinylpyrrolidone and/or copolyvidone, and (3) propylene glycol and/or D-sorbitol; a composition comprising (1) a basic medicament, (2) polyvinylpyrrolidone and/or copolyvidone, and (4) an antioxidant; and a composition comprising (1) a basic medicament, (2) polyvinylpyrrolidone and/or copolyvidone, and (5) a colorant or flavor containing a sulfuric acid or sulfurous acid group.

Abstract: A concentrate package-mix composition comprising a water-soluble pesticide or plant growth regulator, for example a salt of the herbicide glyphosate, and a solid water-insoluble pesticide or plant growth regulator, for example the herbicide flumioxazin, is provided. The water-soluble pesticide or plant growth regulator is dissolved in a continuous aqueous phase of the composition and solid particles of the water-insoluble pesticide or plant growth regulator are suspended in the aqueous phase. These solid particles, individually or plurally, are intimately surrounded by a barrier layer, which comprises either one or both of a water-immiscible organic solvent or an emulsifying agent that has a hydrophile-lipophile balance (HLB) not greater than about 15. Optionally the composition further comprises a viscosity modifying agent, such as colloidal hydrophilic silica, dispersed in the aqueous phase.

Abstract: Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.

Abstract: An insecticidal bait composition which is particularly useful against social insects, such as cockroaches and ants is disclosed. The bait composition comprises a solid or semi-solid bait matrix including a food material for an insect and one or more non-microencapsulated insecticides in an amount effective to act essentially as a primary kill agent and one or more microencapsulated insecticides, excluding pyrethroids, in an amount effective to act essentially as a secondary kill agent, the non-microencapsulated insecticide and microencapsulated insecticide being the same or different.

Abstract: A stabilized insect mating disruption pheromone compositions comprising an insect pheromone and 2,2′-Methylenebis(6-t-butyl-p-cresol). Methods of use and microcapsules containing these compositions are also provided.

Abstract: A process for the manufacturing of microcapsules for sustained release of water soluble peptides, with adjustable release periods of between 1 to 18 weeks. The microcapsule wall are made of a biodegradable polymer. The process is based on the formation of an intermediate complex water/oil/water emulsion. By evaporating the solvent in the emulsion by pressure reduction the microcapsules consolidate, retaining the active peptides in the polymeric matrix. The process produces the complex emulsion in a two mixer, continuous operation. In the first mixer a water/oil emulsion is formed and it is used to form the complex emulsion in the second mixer. By operating in a continuous manner, the process overcome the problems found in existing processes regarding particle size distribution, material losses and process control, among others.

Abstract: The present invention relates to polymeric microspheres as injectable, drug-delivery vehicles for use to deliver bioactive agents to sites within the central nervous system, and for the stimulation of nerve fiber growth by implanting such microspheres within the central nervous system of a patient. Microspheres of less than 45 &mgr;m, preferably less than about 20 &mgr;m, and preferably about 0.1 &mgr;m to about 10 &mgr;m in mean diameter according to the present invention are also selectively taken-up and into astrocytes when delivered directly into the nervous tissues.

Abstract: A controlled release composition comprising an adsorbent polymer, an active agent, and a release retardant is disclosed. The composition has an improved ability to release the active agent over an extended time period.

Abstract: A microcapsule (or microencapsulated product) having a uniform and smooth coating film and also an excellent performance of gradually liberating the content material is produced at a good particle size distribution while suppressing the occurrence of isolated or aggregated film material, aggregated microcapsules and isolated core material. The production process includes: a first coating step of mixing a water-soluble cationic amino resin and an anionic surfactant in the presence of a hydrophobic core material dispersed in an aqueous medium to coat the dispersed core material with a coacervate of the cationic amino resin and the anionic surfactant; and a second coating step of adding an amino resin prepolymer into an aqueous dispersion liquid containing the coated dispersed core material and polycondensating the amino resin prepolymer to further coat the coated dispersed core material with a polycondensate of the amino resin prepolymer.

Abstract: A process for the production of a solid dispersion of at least one therapeutic agent in a hydrophilic carrier having enhanced solubility in an aqueous media comprising dissolving at least one therapeutic agent in a volatile organic solvent containing a very hydrophilic polymer and evaporating the solvent to dryness to form a co-precipitate of therapeutic agent and hydrophilic polymer and the resulting products and their therapeutic method of use.